Age and antiplatelet de-escalation after myocardial infarction in the TALOS-AMI trial.
Seonghyeon Bu, Jaehyuk Jang, Sang Hyun Kim et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of the TALOS-AMI randomized trial evaluated the effects of de-escalating from ticagrelor to clopidogrel on clinical outcomes in patients after myocardial infarction, stratified by age. In patients aged <75 years (n=2376), de-escalation significantly reduced the primary net clinical endpoint (4.1% vs 7.2%; aHR, 0.54 [95% CI, 0.38-0.77]) and bleeding events (2.8% vs 4.9%; aHR, 0.54 [0.35-0.82]). No significant differences were found in patients aged ≥75 years.
Key findings
- In patients aged <75 years, de-escalation reduced the primary endpoint to 4.1% compared to 7.2% with continuation.
- Bleeding events were lower in the de-escalation group for those aged <75 years (2.8% vs 4.9%).
- No significant differences in outcomes were observed for patients aged ≥75 years regarding the primary endpoint or bleeding.
Why it matters
Understanding the differential effects of antiplatelet therapy de-escalation by age can guide clinicians in optimizing treatment strategies for myocardial infarction patients, particularly in balancing efficacy and safety.